JPMorgan Chase & Co. Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective cut by JPMorgan Chase & Co. from $78.00 to $75.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. PTCT has been the subject of a number of other research reports. Cantor […]
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective cut by JPMorgan Chase & Co. from $78.00 to $75.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. PTCT has been the subject of a number of other research reports. Cantor […]
